APO Research
Talk to an analyst

APO RESEARCH · REPORT

Primary Myelofibrosis Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Primary Myelofibrosis Drug Industry Research Report 2026

20 December 2025116 pages

Choose your research edition.

Industry ResearchPrimary Myelofibrosis Drug Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Primary Myelofibrosis Drug Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Primary Myelofibrosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Primary Myelofibrosis Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Primary Myelofibrosis Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Primary Myelofibrosis Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Primary Myelofibrosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Primary Myelofibrosis Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Primary Myelofibrosis Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Primary Myelofibrosis Drug include GSK, Suzhou Zelgen Biopharmaceuticals, Novartis, Bristol Myers Squibb, AbbVie, Incyte, Grunenthal, CTI BioPharma and Celgene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Primary Myelofibrosis Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Primary Myelofibrosis Drug Market by Company

GSK

Suzhou Zelgen Biopharmaceuticals

Novartis

Bristol Myers Squibb

AbbVie

Incyte

Grunenthal

CTI BioPharma

Celgene

Primary Myelofibrosis Drug Segment by Type

JAK 1

JAK 2

Others

Primary Myelofibrosis Drug Segment by Application

Adults

Children

Primary Myelofibrosis Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Primary Myelofibrosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Primary Myelofibrosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Primary Myelofibrosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Primary Myelofibrosis Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Primary Myelofibrosis Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Primary Myelofibrosis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Primary Myelofibrosis Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Primary Myelofibrosis Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Primary Myelofibrosis Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Primary Myelofibrosis Drug Revenue of Manufacturers (2021-2026) Table 9. Global Primary Myelofibrosis Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Primary Myelofibrosis Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Primary Myelofibrosis Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Primary Myelofibrosis Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Primary Myelofibrosis Drug, Product Type & Application Table 14. Global Primary Myelofibrosis Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Primary Myelofibrosis Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. GSK Company Information Table 19. GSK Business Overview Table 20. GSK Primary Myelofibrosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. GSK Primary Myelofibrosis Drug Product Portfolio Table 22. GSK Recent Developments Table 23. Suzhou Zelgen Biopharmaceuticals Company Information Table 24. Suzhou Zelgen Biopharmaceuticals Business Overview Table 25. Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Product Portfolio Table 27. Suzhou Zelgen Biopharmaceuticals Recent Developments Table 28. Novartis Company Information Table 29. Novartis Business Overview Table 30. Novartis Primary Myelofibrosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Novartis Primary Myelofibrosis Drug Product Portfolio Table 32. Novartis Recent Developments Table 33. Bristol Myers Squibb Company Information Table 34. Bristol Myers Squibb Business Overview Table 35. Bristol Myers Squibb Primary Myelofibrosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Bristol Myers Squibb Primary Myelofibrosis Drug Product Portfolio Table 37. Bristol Myers Squibb Recent Developments Table 38. AbbVie Company Information Table 39. AbbVie Business Overview Table 40. AbbVie Primary Myelofibrosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. AbbVie Primary Myelofibrosis Drug Product Portfolio Table 42. AbbVie Recent Developments Table 43. Incyte Company Information Table 44. Incyte Business Overview Table 45. Incyte Primary Myelofibrosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Incyte Primary Myelofibrosis Drug Product Portfolio Table 47. Incyte Recent Developments Table 48. Grunenthal Company Information Table 49. Grunenthal Business Overview Table 50. Grunenthal Primary Myelofibrosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Grunenthal Primary Myelofibrosis Drug Product Portfolio Table 52. Grunenthal Recent Developments Table 53. CTI BioPharma Company Information Table 54. CTI BioPharma Business Overview Table 55. CTI BioPharma Primary Myelofibrosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. CTI BioPharma Primary Myelofibrosis Drug Product Portfolio Table 57. CTI BioPharma Recent Developments Table 58. Celgene Company Information Table 59. Celgene Business Overview Table 60. Celgene Primary Myelofibrosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Celgene Primary Myelofibrosis Drug Product Portfolio Table 62. Celgene Recent Developments Table 63. Global Primary Myelofibrosis Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 64. Global Primary Myelofibrosis Drug Sales by Region (2021-2026) & (k units) Table 65. Global Primary Myelofibrosis Drug Sales Market Share by Region (2021-2026) Table 66. Global Primary Myelofibrosis Drug Sales by Region (2027-2032) & (k units) Table 67. Global Primary Myelofibrosis Drug Sales Market Share by Region (2027-2032) Table 68. Global Primary Myelofibrosis Drug Revenue by Region (2021-2026) & (US$ Million) Table 69. Global Primary Myelofibrosis Drug Revenue Market Share by Region (2021-2026) Table 70. Global Primary Myelofibrosis Drug Revenue by Region (2027-2032) & (US$ Million) Table 71. Global Primary Myelofibrosis Drug Revenue Market Share by Region (2027-2032) Table 72. North America Primary Myelofibrosis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. North America Primary Myelofibrosis Drug Sales by Country (2021-2026) & (k units) Table 74. North America Primary Myelofibrosis Drug Sales by Country (2027-2032) & (k units) Table 75. North America Primary Myelofibrosis Drug Revenue by Country (2021-2026) & (US$ Million) Table 76. North America Primary Myelofibrosis Drug Revenue by Country (2027-2032) & (US$ Million) Table 77. Europe Primary Myelofibrosis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. Europe Primary Myelofibrosis Drug Sales by Country (2021-2026) & (k units) Table 79. Europe Primary Myelofibrosis Drug Sales by Country (2027-2032) & (k units) Table 80. Europe Primary Myelofibrosis Drug Revenue by Country (2021-2026) & (US$ Million) Table 81. Europe Primary Myelofibrosis Drug Revenue by Country (2027-2032) & (US$ Million) Table 82. Asia Pacific Primary Myelofibrosis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Asia Pacific Primary Myelofibrosis Drug Sales by Country (2021-2026) & (k units) Table 84. Asia Pacific Primary Myelofibrosis Drug Sales by Country (2027-2032) & (k units) Table 85. Asia Pacific Primary Myelofibrosis Drug Revenue by Country (2021-2026) & (US$ Million) Table 86. Asia Pacific Primary Myelofibrosis Drug Revenue by Country (2027-2032) & (US$ Million) Table 87. South America Primary Myelofibrosis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. South America Primary Myelofibrosis Drug Sales by Country (2021-2026) & (k units) Table 89. South America Primary Myelofibrosis Drug Sales by Country (2027-2032) & (k units) Table 90. South America Primary Myelofibrosis Drug Revenue by Country (2021-2026) & (US$ Million) Table 91. South America Primary Myelofibrosis Drug Revenue by Country (2027-2032) & (US$ Million) Table 92. Middle East and Africa Primary Myelofibrosis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Middle East and Africa Primary Myelofibrosis Drug Sales by Country (2021-2026) & (k units) Table 94. Middle East and Africa Primary Myelofibrosis Drug Sales by Country (2027-2032) & (k units) Table 95. Middle East and Africa Primary Myelofibrosis Drug Revenue by Country (2021-2026) & (US$ Million) Table 96. Middle East and Africa Primary Myelofibrosis Drug Revenue by Country (2027-2032) & (US$ Million) Table 97. Global Primary Myelofibrosis Drug Sales by Type (2021-2026) & (k units) Table 98. Global Primary Myelofibrosis Drug Sales by Type (2027-2032) & (k units) Table 99. Global Primary Myelofibrosis Drug Sales Market Share by Type (2021-2026) Table 100. Global Primary Myelofibrosis Drug Sales Market Share by Type (2027-2032) Table 101. Global Primary Myelofibrosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 102. Global Primary Myelofibrosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 103. Global Primary Myelofibrosis Drug Revenue Market Share by Type (2021-2026) Table 104. Global Primary Myelofibrosis Drug Revenue Market Share by Type (2027-2032) Table 105. Global Primary Myelofibrosis Drug Price by Type (2021-2026) & (US$/unit) Table 106. Global Primary Myelofibrosis Drug Price by Type (2027-2032) & (US$/unit) Table 107. Global Primary Myelofibrosis Drug Sales by Application (2021-2026) & (k units) Table 108. Global Primary Myelofibrosis Drug Sales by Application (2027-2032) & (k units) Table 109. Global Primary Myelofibrosis Drug Sales Market Share by Application (2021-2026) Table 110. Global Primary Myelofibrosis Drug Sales Market Share by Application (2027-2032) Table 111. Global Primary Myelofibrosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 112. Global Primary Myelofibrosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 113. Global Primary Myelofibrosis Drug Revenue Market Share by Application (2021-2026) Table 114. Global Primary Myelofibrosis Drug Revenue Market Share by Application (2027-2032) Table 115. Global Primary Myelofibrosis Drug Price by Application (2021-2026) & (US$/unit) Table 116. Global Primary Myelofibrosis Drug Price by Application (2027-2032) & (US$/unit) Table 117. Key Raw Materials Table 118. Raw Materials Key Suppliers Table 119. Primary Myelofibrosis Drug Distributors List Table 120. Primary Myelofibrosis Drug Customers List Table 121. Primary Myelofibrosis Drug Industry Trends Table 122. Primary Myelofibrosis Drug Industry Drivers Table 123. Primary Myelofibrosis Drug Industry Restraints Table 124. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Primary Myelofibrosis Drug Product Image Figure 5. Global Primary Myelofibrosis Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Primary Myelofibrosis Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Primary Myelofibrosis Drug Sales (2021-2032) & (k units) Figure 8. Global Primary Myelofibrosis Drug Average Price (US$/unit) & (2021-2032) Figure 9. JAK 1 Product Image Figure 10. JAK 2 Product Image Figure 11. Others Product Image Figure 12. Adults Product Image Figure 13. Children Product Image Figure 14. Global Primary Myelofibrosis Drug Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Primary Myelofibrosis Drug, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Primary Myelofibrosis Drug Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Primary Myelofibrosis Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Primary Myelofibrosis Drug Sales by Region in 2025 Figure 20. Global Primary Myelofibrosis Drug Revenue by Region in 2025 Figure 21. North America Primary Myelofibrosis Drug Market Size by Country in 2025 Figure 22. North America Primary Myelofibrosis Drug Sales Market Share by Country (2021-2032) Figure 23. North America Primary Myelofibrosis Drug Revenue Market Share by Country (2021-2032) Figure 24. United States Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Primary Myelofibrosis Drug Market Size by Country in 2025 Figure 28. Europe Primary Myelofibrosis Drug Sales Market Share by Country (2021-2032) Figure 29. Europe Primary Myelofibrosis Drug Revenue Market Share by Country (2021-2032) Figure 30. Germany Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Primary Myelofibrosis Drug Market Size by Country in 2025 Figure 41. Asia Pacific Primary Myelofibrosis Drug Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Primary Myelofibrosis Drug Revenue Market Share by Country (2021-2032) Figure 43. China Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Primary Myelofibrosis Drug Market Size by Country in 2025 Figure 52. South America Primary Myelofibrosis Drug Sales Market Share by Country (2021-2032) Figure 53. South America Primary Myelofibrosis Drug Revenue Market Share by Country (2021-2032) Figure 54. Brazil Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Primary Myelofibrosis Drug Market Size by Country in 2025 Figure 58. Middle East and Africa Primary Myelofibrosis Drug Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Primary Myelofibrosis Drug Revenue Market Share by Country (2021-2032) Figure 60. Egypt Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Primary Myelofibrosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Primary Myelofibrosis Drug Sales Market Share by Type (2021-2032) Figure 66. Global Primary Myelofibrosis Drug Revenue Market Share by Type (2021-2032) Figure 67. Global Primary Myelofibrosis Drug Price (US$/unit) by Type (2021-2032) Figure 68. Global Primary Myelofibrosis Drug Sales Market Share by Application (2021-2032) Figure 69. Global Primary Myelofibrosis Drug Revenue Market Share by Application (2021-2032) Figure 70. Global Primary Myelofibrosis Drug Price (US$/unit) by Application (2021-2032) Figure 71. Primary Myelofibrosis Drug Value Chain Figure 72. Primary Myelofibrosis Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Primary Myelofibrosis Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • JAK 1
  • JAK 2
  • Others
Applications
  • Adults
  • Children
Companies covered
  • GSK
  • Suzhou Zelgen Biopharmaceuticals
  • Novartis
  • Bristol Myers Squibb
  • AbbVie
  • Incyte
  • Grunenthal
  • CTI BioPharma
  • Celgene

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Primary Myelofibrosis Drug Market Size (2021-2032)
  4. 2.2.2 Global Primary Myelofibrosis Drug Sales (2021-2032)
  5. 2.2.3 Global Primary Myelofibrosis Drug Market Average Price (2021-2032)
  6. 2.3 Primary Myelofibrosis Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 JAK 1
  9. 2.3.3 JAK 2
  10. 2.3.4 Others
  11. 2.4 Primary Myelofibrosis Drug by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Adults
  14. 2.4.3 Children
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Primary Myelofibrosis Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Primary Myelofibrosis Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Primary Myelofibrosis Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Primary Myelofibrosis Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Primary Myelofibrosis Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Primary Myelofibrosis Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Primary Myelofibrosis Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Primary Myelofibrosis Drug, Established Date
  9. 3.9 Global Primary Myelofibrosis Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 GSK
  2. 4.1.1 GSK Company Information
  3. 4.1.2 GSK Business Overview
  4. 4.1.3 GSK Primary Myelofibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 GSK Primary Myelofibrosis Drug Product Portfolio
  6. 4.1.5 GSK Recent Developments
  7. 4.2 Suzhou Zelgen Biopharmaceuticals
  8. 4.2.1 Suzhou Zelgen Biopharmaceuticals Company Information
  9. 4.2.2 Suzhou Zelgen Biopharmaceuticals Business Overview
  10. 4.2.3 Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Product Portfolio
  12. 4.2.5 Suzhou Zelgen Biopharmaceuticals Recent Developments
  13. 4.3 Novartis
  14. 4.3.1 Novartis Company Information
  15. 4.3.2 Novartis Business Overview
  16. 4.3.3 Novartis Primary Myelofibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Novartis Primary Myelofibrosis Drug Product Portfolio
  18. 4.3.5 Novartis Recent Developments
  19. 4.4 Bristol Myers Squibb
  20. 4.4.1 Bristol Myers Squibb Company Information
  21. 4.4.2 Bristol Myers Squibb Business Overview
  22. 4.4.3 Bristol Myers Squibb Primary Myelofibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Bristol Myers Squibb Primary Myelofibrosis Drug Product Portfolio
  24. 4.4.5 Bristol Myers Squibb Recent Developments
  25. 4.5 AbbVie
  26. 4.5.1 AbbVie Company Information
  27. 4.5.2 AbbVie Business Overview
  28. 4.5.3 AbbVie Primary Myelofibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 AbbVie Primary Myelofibrosis Drug Product Portfolio
  30. 4.5.5 AbbVie Recent Developments
  31. 4.6 Incyte
  32. 4.6.1 Incyte Company Information
  33. 4.6.2 Incyte Business Overview
  34. 4.6.3 Incyte Primary Myelofibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Incyte Primary Myelofibrosis Drug Product Portfolio
  36. 4.6.5 Incyte Recent Developments
  37. 4.7 Grunenthal
  38. 4.7.1 Grunenthal Company Information
  39. 4.7.2 Grunenthal Business Overview
  40. 4.7.3 Grunenthal Primary Myelofibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Grunenthal Primary Myelofibrosis Drug Product Portfolio
  42. 4.7.5 Grunenthal Recent Developments
  43. 4.8 CTI BioPharma
  44. 4.8.1 CTI BioPharma Company Information
  45. 4.8.2 CTI BioPharma Business Overview
  46. 4.8.3 CTI BioPharma Primary Myelofibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 CTI BioPharma Primary Myelofibrosis Drug Product Portfolio
  48. 4.8.5 CTI BioPharma Recent Developments
  49. 4.9 Celgene
  50. 4.9.1 Celgene Company Information
  51. 4.9.2 Celgene Business Overview
  52. 4.9.3 Celgene Primary Myelofibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Celgene Primary Myelofibrosis Drug Product Portfolio
  54. 4.9.5 Celgene Recent Developments
5 Global Primary Myelofibrosis Drug Market Scenario by Region
  1. 5.1 Global Primary Myelofibrosis Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Primary Myelofibrosis Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Primary Myelofibrosis Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Primary Myelofibrosis Drug Sales by Region: 2027-2032
  5. 5.3 Global Primary Myelofibrosis Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Primary Myelofibrosis Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Primary Myelofibrosis Drug Revenue by Region: 2027-2032
  8. 5.4 North America Primary Myelofibrosis Drug Market Facts & Figures by Country
  9. 5.4.1 North America Primary Myelofibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Primary Myelofibrosis Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Primary Myelofibrosis Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Primary Myelofibrosis Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Primary Myelofibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Primary Myelofibrosis Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Primary Myelofibrosis Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Primary Myelofibrosis Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Primary Myelofibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Primary Myelofibrosis Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Primary Myelofibrosis Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Primary Myelofibrosis Drug Market Facts & Figures by Country
  41. 5.7.1 South America Primary Myelofibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Primary Myelofibrosis Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Primary Myelofibrosis Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Primary Myelofibrosis Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Primary Myelofibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Primary Myelofibrosis Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Primary Myelofibrosis Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Primary Myelofibrosis Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Primary Myelofibrosis Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Primary Myelofibrosis Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Primary Myelofibrosis Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Primary Myelofibrosis Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Primary Myelofibrosis Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Primary Myelofibrosis Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Primary Myelofibrosis Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Primary Myelofibrosis Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Primary Myelofibrosis Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Primary Myelofibrosis Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Primary Myelofibrosis Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Primary Myelofibrosis Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Primary Myelofibrosis Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Primary Myelofibrosis Drug Value Chain Analysis
  2. 8.1.1 Primary Myelofibrosis Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Primary Myelofibrosis Drug Production Mode & Process
  5. 8.2 Primary Myelofibrosis Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Primary Myelofibrosis Drug Distributors
  8. 8.2.3 Primary Myelofibrosis Drug Customers
9 Global Primary Myelofibrosis Drug Analyzing Market Dynamics
  1. 9.1 Primary Myelofibrosis Drug Industry Trends
  2. 9.2 Primary Myelofibrosis Drug Industry Drivers
  3. 9.3 Primary Myelofibrosis Drug Industry Opportunities and Challenges
  4. 9.4 Primary Myelofibrosis Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst